XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated
 3 Months Ended
Oct. 31, 2023
Broad Atlantic Associates LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 100.00%
IDT R.E. Holdings Ltd [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation Israel
Percentage Owned 100.00%
Rafael Holdings Realty, Inc [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 100.00%
Barer Institute, Inc. [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware [1]
Percentage Owned 100.00%
Hillview Avenue Realty, JV [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 100.00%
Hillview Avenue Realty, LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 100.00%
Rafael Medical Devices, Inc. [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 68.00% [2]
Levco Pharmaceuticals Ltd. [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation Israel
Percentage Owned 95.00% [3]
Farber Partners, LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 93.00%
Pharma Holdings, LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 90.00%
LipoMedix Pharmaceuticals Ltd. [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation Israel
Percentage Owned 95.00% [4]
Altira Capital & Consulting, LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 67.00%
CS Pharma Holdings, LLC [Member]  
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]  
Country of Incorporation United States – Delaware
Percentage Owned 45.00% [5]
[1] In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.
[2] In August 2023, the Company raised $925,000 from third parties in exchange for 31.62% ownership of Rafael Medical Devices. As of July 31, 2023, the Company recorded $825,000 of the funds received related to the sale within prepaid expenses and other current assets and other liabilities within the consolidated balance sheets.
[3] During Fiscal 2022, the Company discontinued further material investment in Levco. In August 2023, Levco was dissolved.
[4] On February 9, 2023, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd. from 84% to 95%.
[5] 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma and Pharma Holdings, collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis. Refer to Note 4 for further details.